Indonesian Political, Business & Finance News

To Prevent High Medicine Prices, Constitutional Court Limits New Patent Grants

| | Source: Media Indonesia Translated from Indonesian | Legal
To Prevent High Medicine Prices, Constitutional Court Limits New Patent Grants
Image: Media Indonesia

The Constitutional Court (MK) has revived regulations that limit the granting of new patents for existing drugs or products. This move is intended to prevent companies from extending monopolies through modifications or new uses of drugs that do not provide significant medical benefits.

The decision was rendered in Case Number 255/PUU-XXIII/2025 regarding the judicial review of Law Number 65 of 2024 concerning Patents. The Court partially granted the petition, declaring that the removal of Article 4 letter f of the Patent Law contradicts the 1945 Constitution of the Republic of Indonesia.

With this ruling, the Court reinstates Article 4 letter f of Law Number 13 of 2016. The regulation states that new uses of existing products cannot be patented, nor can new forms of existing compounds if they do not provide a significant increase in efficacy.

Constitutional Judge M. Guntur Hamzah stated that the rule is necessary to protect the public while providing legal certainty for the national generic drug industry.

“In the Court’s view, the prohibition of second medical use, as regulated in the norm of Article 4 letter f of Law 13/2016, is a state protection measure that is far more beneficial and provides greater legal certainty for the national generic drug industry,” Guntur said while reading the court’s considerations in Jakarta on Friday.

According to Guntur, the regulation provides protection from the early stages of patent registration, thereby strengthening public health protection.

“By prohibiting second medical use at the early phase of patent registration, it will strengthen the public health protection system from upstream to downstream, thus ensuring the realisation of national health sovereignty,” he added.

The Court assessed that the rule is vital because patent protection must continue to consider the public’s right to health, as guaranteed in Article 28H paragraph (1) of the 1945 Constitution.

Guntur noted that while the government possesses several mechanisms to address patent issues—such as compulsory licensing, parallel imports, the Bolar provision, and government-executed patents—these mechanisms are often only utilised after problems have already arisen.

“However, those instruments rely more on downstream patent resolution in the pharmaceutical sector, making them ineffective in avoiding ‘evergreening’ patent practices, which directly impact the public’s limited access to affordable medicines,” said Guntur.

Evergreening refers to efforts to extend patent monopolies by filing new patents for changes or new uses of existing products.

In addition to reinstating Article 4 letter f of Law 13/2016, the Court declared that the explanation of this article in Law 65/2024 contradicts the 1945 Constitution and is conditionally without binding legal force. The Court found that the previous explanation in Law 65/2024 allowed for second medical use, which is no longer permissible following the reinstatement of the 2016 regulation.

The Court also requested that lawmakers adjust the Patent Law to align with this decision. This is because Law 65/2024 includes the word ‘use’ within the definition of an invention or something eligible for a patent. Without adjustment, there are concerns that this could create a loophole for filing new patents on the use of existing drugs even without significant improvements in efficacy.

“Therefore, the Court emphasises that lawmakers must carry out adjustments to the patent law in accordance with this Court’s decision,” Guntur stated.

The case was brought forward by several organisations working on health, patient rights, and global justice issues. The petitioners argued that the removal of Article 4 letter f of Law 13/2016 had reduced public protection by opening opportunities for patents on new uses of existing products. They further argued that such changes could hinder access to affordable medicines as companies could maintain monopolies through new patent filings, violating the rights to fair legal certainty and health guaranteed by the Constitution.

More from 31 August 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/to-prevent-high-medicine-prices-constitutional-court-limits-new-patent-grants-1788155598)
Originally published by Media Indonesia (https://mediaindonesia.com/kesehatan/927844/cegah-harga-obat-mahal-mk-batasi-pemberian-paten-baru), translated from Indonesian
Print